Your browser is no longer supported. Please, upgrade your browser.
TGTX TG Therapeutics, Inc. daily Stock Chart
TG Therapeutics, Inc.
Index- P/E- EPS (ttm)-2.01 Insider Own0.60% Shs Outstand105.46M Perf Week22.48%
Market Cap2.89B Forward P/E- EPS next Y-1.20 Insider Trans-1.05% Shs Float84.91M Perf Month33.15%
Income-188.80M PEG- EPS next Q-0.34 Inst Own54.40% Short Float14.75% Perf Quarter144.22%
Sales0.20M P/S14465.13 EPS this Y14.90% Inst Trans11.55% Short Ratio5.36 Perf Half Y104.98%
Book/sh-0.01 P/B- EPS next Y23.60% ROA-162.50% Target Price- Perf Year189.91%
Cash/sh0.65 P/C36.90 EPS next 5Y- ROE- 52W Range4.95 - 22.78 Perf YTD114.95%
Dividend- P/FCF- EPS past 5Y-3.60% ROI-249.30% 52W High4.74% Beta2.46
Dividend %- Quick Ratio1.40 Sales past 5Y-0.10% Gross Margin- 52W Low382.02% ATR1.36
Employees153 Current Ratio1.40 Sales Q/Q0.00% Oper. Margin- RSI (14)72.21 Volatility7.67% 6.93%
OptionableYes Debt/Eq- EPS Q/Q-17.70% Profit Margin- Rel Volume1.56 Prev Close22.62
ShortableYes LT Debt/Eq- Earnings- Payout- Avg Volume2.33M Price23.86
Recom1.70 SMA2026.15% SMA5030.50% SMA20098.17% Volume3,631,371 Change5.48%
Jun-05-20Initiated Evercore ISI Outperform $60
Jan-17-20Reiterated H.C. Wainwright Buy $20 → $24
Nov-27-19Resumed B. Riley FBR Buy $12
Feb-06-19Resumed Jefferies Buy $8
Sep-25-18Downgrade Raymond James Strong Buy → Outperform
Mar-09-18Reiterated B. Riley FBR, Inc. Buy $21.50 → $27
Dec-01-17Resumed B. Riley FBR, Inc. Buy $21.50
Nov-14-17Resumed H.C. Wainwright Buy $33
Apr-25-17Initiated Jefferies Buy
Mar-06-17Reiterated FBR & Co. Outperform $24 → $26
Oct-06-16Resumed Brean Capital Buy $28
May-27-16Initiated SunTrust Buy $18
Dec-01-15Initiated FBR Capital Outperform $29
Sep-09-15Initiated Raymond James Strong Buy
Aug-12-15Resumed H.C. Wainwright Buy $22
Jun-19-15Reiterated Brean Capital Buy $22 → $28
Dec-11-14Reiterated ROTH Capital Buy $25 → $33
Dec-10-14Reiterated ROTH Capital Buy $25 → $33
Oct-27-14Initiated H.C. Wainwright Buy $17
Sep-25-14Reiterated Brean Capital Buy $19 → $22
Jul-08-20 07:00AM  
Jun-22-20 09:00AM  
Jun-17-20 07:00AM  
Jun-16-20 07:00AM  
Jun-12-20 07:00AM  
Jun-09-20 05:29PM  
Jun-08-20 12:52PM  
Jun-02-20 07:00AM  
May-29-20 08:15AM  
May-15-20 07:00AM  
May-14-20 10:08PM  
May-11-20 04:12PM  
May-08-20 07:00AM  
May-06-20 10:13AM  
May-05-20 07:00AM  
May-01-20 12:30PM  
Apr-29-20 07:20AM  
Mar-25-20 12:00PM  
Mar-22-20 10:39AM  
Mar-09-20 08:00AM  
Mar-05-20 11:00AM  
Mar-03-20 07:00AM  
Feb-28-20 07:30AM  
Jan-21-20 09:57AM  
Jan-17-20 08:07AM  
Jan-16-20 07:30AM  
Jan-10-20 08:56AM  
Dec-24-19 09:54AM  
Dec-23-19 07:30AM  
Dec-10-19 02:36PM  
Dec-09-19 08:58AM  
Dec-08-19 09:00AM  
Dec-07-19 08:35AM  
Dec-06-19 07:30AM  
Dec-03-19 09:29PM  
Nov-18-19 07:30AM  
Nov-12-19 07:34AM  
Nov-08-19 07:30AM  
Nov-06-19 09:15AM  
Nov-01-19 11:49AM  
Oct-30-19 05:15AM  
Oct-28-19 07:00AM  
Oct-24-19 07:30AM  
Oct-23-19 02:16PM  
Oct-02-19 07:30AM  
Sep-30-19 07:30AM  
Sep-23-19 07:30AM  
Sep-20-19 07:30AM  
Sep-17-19 01:33PM  
Sep-12-19 07:38AM  
Aug-29-19 07:30AM  
Aug-26-19 12:00PM  
Aug-16-19 06:58AM  
Aug-12-19 04:52PM  
Aug-09-19 03:23PM  
Aug-07-19 04:05PM  
Jul-31-19 01:48PM  
Jul-09-19 10:43PM  
Jul-05-19 05:14PM  
Jul-02-19 07:30AM  
Jun-30-19 11:46PM  
Jun-27-19 12:27PM  
Jun-18-19 07:30AM  
Jun-17-19 07:30AM  
Jun-11-19 07:58AM  
Jun-04-19 04:02PM  
May-28-19 09:28AM  
May-23-19 07:20PM  
May-16-19 07:30AM  
May-10-19 01:23PM  
May-09-19 07:30AM  
May-07-19 09:00AM  
Apr-17-19 11:13AM  
Apr-16-19 09:28PM  
Apr-15-19 07:30AM  
Apr-10-19 01:40PM  
Apr-08-19 10:00AM  
Apr-02-19 09:27AM  
Apr-01-19 01:46PM  
Mar-29-19 04:00PM  
TG Therapeutics, Inc., a biopharmaceutical company, engages in developing and delivering medicines for patients with chronic lymphocytic leukemia (CLL), non-Hodgkin's Lymphoma (NHL), and multiple sclerosis (MS). The company develops a robust B-cell directed research and development platform for identification of key B-cell pathways of interest and rapid clinical testing. It also develops Ublituximab, a novel anti-CD20 monoclonal antibody, which is in Phase III pivotal study for the treatment of CLL and MS; Umbralisib, a dual PI3K delta and CK1 epsilon inhibitor, which is in Phase III pivotal study for the treatment of CLL, and Phase 2b pivotal study for the treatment of marginal zone lymphoma and follicular lymphoma. In addition, the company develops TG-1501, an anti-PD-L1 monoclonal antibody, which is in Phase I pivotal study for the treatment of B-cell cancers; TG-1701, an oral Bruton's Tyrosine Kinase, which is in Phase I pivotal study for the treatment of B-cell cancers; and TG-1801, an anti-CD47/CD19 bispecific antibody that is in Phase I pivotal study for the treatment of B-cell cancers. TG Therapeutics, Inc. has strategic alliances with LFB Biotechnologies S.A.S; GTC Biotherapeutics; LFB/GTC LLC; Ildong Pharmaceutical Co. Ltd.; Rhizen Pharmaceuticals, S A; Checkpoint Therapeutics, Inc.; Jiangsu Hengrui Medicine Co.; Novimmune SA; Ligand Pharmaceuticals Incorporated; and Jubilant Biosys. TG Therapeutics, Inc. was incorporated in 1993 and is headquartered in New York, New York.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
KENNEDY WILLIAM JAMESDirectorJun 17Sale18.277,745141,50194,633Jun 24 07:48 PM